Protalix BioTherapeutics to Hold Second Quarter 2019 Financial Results and Corporate Update Conference Call on August 8, 2019...
July 29 2019 - 04:01PM
Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a
biopharmaceutical company focused on the development and
commercialization of recombinant therapeutic proteins expressed
through its proprietary plant cell-based expression system,
ProCellEx®, today announced that it will report second quarter 2019
financial results and provide a corporate update on Thursday,
August 8, 2019 at 8:30 am ET.
To participate in the conference call, please dial the following
numbers prior to the start of the call: United States: +1
(844) 358-6760; International: +1 (478) 219-0004. Conference
ID number: 1497319.
The conference call will also be broadcast live and available
for replay for two weeks on the Company’s website,
www.protalix.com, in the Events Calendar of the Investors section.
Please access the Company’s website at least 15 minutes ahead
of the conference to register, download, and install any necessary
audio software.
About Protalix BioTherapeutics,
Inc.
Protalix is a biopharmaceutical company focused on the
development and commercialization of recombinant therapeutic
proteins expressed through its proprietary plant cell-based
expression system, ProCellEx®. Protalix’s unique expression
system presents a proprietary method for developing recombinant
proteins in a cost-effective, industrial-scale manner.
Protalix’s first product manufactured by ProCellEx,
taliglucerase alfa, was approved for marketing by the
U.S. Food and Drug Administration (FDA) in May 2012 and,
subsequently, by the regulatory authorities of other countries.
Protalix has licensed to Pfizer Inc. the worldwide
development and commercialization rights for taliglucerase alfa,
excluding Brazil, where Protalix retains full rights.
Protalix’s development pipeline includes the following product
candidates: pegunigalsidase alfa, a modified version of the
recombinant human alpha-GAL-A protein for the treatment of Fabry
disease; OPRX-106, an orally-delivered anti-inflammatory treatment;
alidornase alfa for the treatment of Cystic Fibrosis; and
others. Protalix has partnered with Chiesi Farmaceutici
S.p.A., both in the United States and outside the United States,
for the development and commercialization of pegunigalsidase
alfa.
Investor Contact
Alan Lada, Vice President Solebury Trout 617-221-8006
alada@soleburytrout.com
Protalix BioTherapeutics (AMEX:PLX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Protalix BioTherapeutics (AMEX:PLX)
Historical Stock Chart
From Mar 2023 to Mar 2024